516 related articles for article (PubMed ID: 24231837)
21. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.
Abrams P; Freeman R; Anderström C; Mattiasson A
Br J Urol; 1998 Jun; 81(6):801-10. PubMed ID: 9666761
[TBL] [Abstract][Full Text] [Related]
22. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
Appell RA; Sand P; Dmochowski R; Anderson R; Zinner N; Lama D; Roach M; Miklos J; Saltzstein D; Boone T; Staskin DR; Albrecht D;
Mayo Clin Proc; 2001 Apr; 76(4):358-63. PubMed ID: 11322350
[TBL] [Abstract][Full Text] [Related]
23. Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome.
Chapple CR; Abrams P; Andersson KE; Radziszewski P; Masuda T; Small M; Kuwayama T; Deacon S
J Urol; 2014 Jan; 191(1):253-60. PubMed ID: 24018240
[TBL] [Abstract][Full Text] [Related]
24. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
25. Transdermal oxybutynin for overactive bladder.
Davila GW; Starkman JS; Dmochowski RR
Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study.
MacDiarmid SA; Peters KM; Chen A; Armstrong RB; Orman C; Aquilina JW; Nitti VW
Mayo Clin Proc; 2008 Sep; 83(9):1002-10. PubMed ID: 18775200
[TBL] [Abstract][Full Text] [Related]
27. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial.
Staskin D; Sand P; Zinner N; Dmochowski R;
J Urol; 2007 Sep; 178(3 Pt 1):978-83; discussion 983-4. PubMed ID: 17632131
[TBL] [Abstract][Full Text] [Related]
28. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.
Herschorn S; Barkin J; Castro-Diaz D; Frankel JM; Espuna-Pons M; Gousse AE; Stölzel M; Martin N; Gunther A; Van Kerrebroeck P
Urology; 2013 Aug; 82(2):313-20. PubMed ID: 23769122
[TBL] [Abstract][Full Text] [Related]
29. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
Alloussi S; Mürtz G; Braun R; Gerhardt U; Heinrich M; Hellmis E; Horn W; Marschall-Kehrel D; Niklas K; Raabe M; Rössler T; Seibt B; Siemer S; Schultz-Lampel D; Walter H; Wiedeking B; Alloussi S; Bock P; Strugala G; Madersbacher H
BJU Int; 2010 Aug; 106(4):550-6. PubMed ID: 20002668
[TBL] [Abstract][Full Text] [Related]
30. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
[TBL] [Abstract][Full Text] [Related]
31. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis.
Appell RA
Urology; 1997 Dec; 50(6A Suppl):90-6; discussion 97-9. PubMed ID: 9426760
[TBL] [Abstract][Full Text] [Related]
33. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
[TBL] [Abstract][Full Text] [Related]
34. Clinical Efficacy and Tolerability of the Nicotinic Channel Modulator Dexmecamylamine in Subjects with Overactive Bladder.
Chancellor M; Versi E; Dvergsten C; Toler S
J Urol; 2015 Nov; 194(5):1329-35. PubMed ID: 26073872
[TBL] [Abstract][Full Text] [Related]
35. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.
Frenkl TL; Zhu H; Reiss T; Seltzer O; Rosenberg E; Green S
J Urol; 2010 Aug; 184(2):616-22. PubMed ID: 20639026
[TBL] [Abstract][Full Text] [Related]
36. Considering the prominent complaint as a guide in medical therapy for overactive bladder syndrome in women over 45 years.
Jafarabadi M; Jafarabadi L; Shariat M; Rabie Salehi G; Haghollahi F; Rashidi BH
J Obstet Gynaecol Res; 2015 Jan; 41(1):120-6. PubMed ID: 25369726
[TBL] [Abstract][Full Text] [Related]
37. Trospium chloride for the treatment of overactive bladder with urge incontinence.
Singh-Franco D; Machado C; Tuteja S; Zapantis A
Clin Ther; 2005 May; 27(5):511-30. PubMed ID: 15978301
[TBL] [Abstract][Full Text] [Related]
38. An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study.
Aaron LE; Morris TJ; Jahshan P; Reiz JL
Curr Med Res Opin; 2012 Aug; 28(8):1369-79. PubMed ID: 22769237
[TBL] [Abstract][Full Text] [Related]
39. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
Stöhrer M; Mürtz G; Kramer G; Schnabel F; Arnold EP; Wyndaele JJ;
Eur Urol; 2007 Jan; 51(1):235-42. PubMed ID: 16698176
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial.
Lackner TE; Wyman JF; McCarthy TC; Monigold M; Davey C
J Am Med Dir Assoc; 2011 Nov; 12(9):639-47. PubMed ID: 21450183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
